Skip to content

Yokohama Heart Failure Investigators:Time Zone Dynamics of Serum Arginine-Vasopressin and Urine Aquaporin-2 on Acute Decompensated Heart Failure in the Patients with Depressed Left Ventricular Function

Yokohama Heart Failure Investigators:Time Zone Dynamics of Serum Arginine-Vasopressin and Urine Aquaporin-2 on Acute Decompensated Heart Failure in the Patients with Depressed Left Ventricular Function - T-Dynosaur

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018717
Enrollment
16
Registered
2015-08-19
Start date
2015-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute congestive heart failure

Interventions

tolvaptan morning administering group: Tolvaptan is administered in the morning from the third through fifth in-hospital day (3days) tolvaptan before-sleep administering group: Tolvaptan is administer

Sponsors

National Hospital Organization Yokohama Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) patient older than 20 years old 2) Patient who is treated acute heart failure presenting clinical scenarios 1 and 2 with carperitide under bladder catheterization 3) patient who is planed to administer tolvaptan because of insufficient diuresis only by intravenous injection frosemide 4) patient with chronic kidney disease (eGFR<60ml/min/1.73m2) 5)patient with depressed left ventricular function (left ventricle ejection fraction <55% or left ventricle shortening rate <26%) 6)patient from whom consent for participation in this clinical study was obtained

Exclusion criteria

Exclusion criteria: 1)patient with acute heart failure presenting clinical scenarios 3, 4, and 5 2)patient to whom tolvaptan has already been administered 3)patient to whom continuous intravenous infusion inotropes (catecholamine, phosphodiesterase-3 inhibitors, colforsin daropate hydrochloride, etc) has already been administered or is planned to be administered 4)patient who has received mechanical support (invasive mechanical ventilation, intraaortic balloon pumping, percutaneous cardiopulmonary support, continuation hemofiltration-dialysis, etc.) or is planned to use it 5)patient who presents shock at enrollment 6)Patient with advanced renal dysfunction (eGFR<30ml/min/1.73m2) 7)patient who is judged to be improper by the doctor in charge

Design outcomes

Primary

MeasureTime frame
urine volume per 6 hours

Secondary

MeasureTime frame
Relationship between urine AQP2, serume AVP and diuresis effect of tolvaptan

Countries

Japan

Contacts

Public ContactYoichi Ajiro

National Hospital Organization Yokohama Medical Center Department of Cardiology

aziro-youichi@yokohamamc.jp+81-45-851-2621

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026